Prostate Cancer

Adding Chemotherapy Improves Survival for Men with High-Risk, Localized Prostate Cancer

ASCO Annual Meeting
May 30, 2015

A recent study shows that adding docetaxel (Docefrez, Taxotere) chemotherapy to the standard treatment of hormone therapy and radiation therapy helps men with high-risk, localized prostate cancer live longer. Having a high-risk, localized prostate cancer means that the tumor has grown throughout the prostate gland, the tumor has a high grade or Gleason score, and the man has a high prostate-specific antigen (PSA) level. The Gleason score is based on how much the tumor looks like healthy tissue when viewed under a microscope.

Adding Docetaxel to Standard Prostate Cancer Treatment Lengthens Lives

ASCO Annual Meeting
May 13, 2015

A large, ongoing study showed that men with advanced prostate cancer who received docetaxel (Docefrez, Taxotere) in addition to standard prostate cancer treatment lived longer than those who received only standard hormone therapy. The study also showed that including zoledronic acid (Zometa) along with docetaxel and standard hormone therapy did not offer additional benefits.

Preliminary Evidence Shows Increase in Higher-Risk Prostate Cancers Between 2011 and 2013

Genitourinary Cancers Symposium
February 23, 2015

A new study that analyzed data from more than 87,500 men with prostate cancer shows that the number diagnosed with higher-risk disease increased between 2011 and 2013. According to these results, the number of men diagnosed with either intermediate- or high-risk disease has increased by nearly 6% since 2011. These findings are interesting because in 2011 the U.S. Preventive Services Task Force (USPSTF) recommended that PSA testing not be used for prostate cancer screening, regardless of a man’s age.

Blood Test May Help Predict Most Effective Treatment for Castration-Resistant Prostate Cancer in the Future

Genitourinary Cancers Symposium
February 23, 2015

For many types of cancer, doctors are able to run laboratory tests to identify specific genes, proteins, and other factors unique to the tumor that help determine the best treatment option for each patient. However, there are currently no tests to help doctors select the best treatment option for men with metastatic castration-resistant prostate cancer (mCRPC).

Active Surveillance for Intermediate-Risk Prostate Cancer Linked With Decreased Survival

Genitourinary Cancers Symposium
February 23, 2015

A new study that analyzed data from 945 men with prostate cancer raises questions about recommending active surveillance to men with intermediate-risk disease. Compared to men with low-risk prostate cancer, those with intermediate-risk disease had a nearly four-times higher chance of dying from prostate cancer within 15 years when their disease was managed using active surveillance.

Pages

Subscribe to RSS - Prostate Cancer